论文部分内容阅读
目的:评价同步放化疗治疗中晚期宫颈癌的疗效。方法:将中晚期宫颈癌患者161例随机分为两组:同步放化疗组81例,采用紫杉醇+顺铂周疗,同时行根治性放疗,体外放疗+192Ir腔内放疗。单纯放疗组80例行根治性放疗,放疗方法同同步放化疗组。结果:同步放化疗组与单纯放疗组有效率分别为87.65%和56.25%,两组差异有统计学意义,P<0.05。同步放化疗组与单纯放疗组的3年生存率分别为75.3%和57.5%,差异有统计学意义,P<0.05。同步放化疗组骨髓抑制及消化道反应发生率均高于单纯放疗组,P<0.05。及时对症治疗后,患者均可耐受。远期直肠膀胱并发症未见增加。结论:同步放化疗治疗中晚期宫颈癌可提高近期疗效及3年生存率。
Objective: To evaluate the efficacy of concurrent chemoradiotherapy in the treatment of advanced cervical cancer. Methods: 161 cases of advanced cervical cancer were randomly divided into two groups: 81 cases of concurrent radiotherapy and chemotherapy group, the use of paclitaxel + cisplatin week treatment, while radical radiotherapy, radiotherapy in vitro + 192Ir cavity radiotherapy. Radical radiotherapy group 80 cases of radical radiotherapy, radiotherapy method with the same radiotherapy and chemotherapy group. Results: The effective rates of concurrent chemoradiotherapy and radiotherapy alone were 87.65% and 56.25%, respectively, with significant difference between the two groups (P <0.05). The 3-year survival rates of concurrent chemoradiotherapy group and radiotherapy alone group were 75.3% and 57.5%, respectively, with statistical significance (P <0.05). The incidence of myelosuppression and gastrointestinal reaction in concurrent chemoradiotherapy group were higher than those in radiotherapy alone group, P <0.05. Timely symptomatic treatment, patients can tolerate. Long-term rectal bladder complications no increase. Conclusions: Simultaneous chemoradiotherapy for advanced cervical cancer can improve the short-term efficacy and 3-year survival rate.